Biospace news

Syndicate content
RSS Feed for Biotech, Pharmaceutical and Clinical Research News | BioSpace (Generated by New Sloth)
Updated: 8 hours 34 min ago

Takeda Cuts Jobs in California Following Massachusetts Layoffs (Updated)

Wed, 05/24/2023 - 02:00
Takeda Cuts Jobs in California Following Massachusetts Layoffs (Updated) 5/24/2023

FDA Approves First Nasal Nalmefene Spray for Opioid Overdose

Tue, 05/23/2023 - 02:00
FDA Approves First Nasal Nalmefene Spray for Opioid Overdose 5/23/2023

Roche Terminates Second Phase II Schizophrenia Trial

Tue, 05/23/2023 - 02:00
Roche Terminates Second Phase II Schizophrenia Trial 5/23/2023

ReNAgade Launches with $300M to More Easily Deliver RNA Medicines

Tue, 05/23/2023 - 02:00
ReNAgade Launches with $300M to More Easily Deliver RNA Medicines 5/23/2023

Ironwood to Pay $1B to Acquire VectivBio, Late-Stage Digestive Therapy

Tue, 05/23/2023 - 02:00
Ironwood to Pay $1B to Acquire VectivBio, Late-Stage Digestive Therapy 5/23/2023

Billy Dunn’s Prothena Board Position Reignites Ethical Debate

Tue, 05/23/2023 - 02:00
Billy Dunn’s Prothena Board Position Reignites Ethical Debate 5/23/2023

Blueprint Adds Indolent Systemic Mastocytosis to Ayvakit’s Label

Tue, 05/23/2023 - 02:00
Blueprint Adds Indolent Systemic Mastocytosis to Ayvakit’s Label 5/23/2023

10 Pharma Tech Jobs Available Now

Tue, 05/23/2023 - 02:00
10 Pharma Tech Jobs Available Now 5/23/2023

AbbVie, Genmab Score FDA Nod for DLBCL as Blood Cancer Space Heats Up

Mon, 05/22/2023 - 02:00
AbbVie, Genmab Score FDA Nod for DLBCL as Blood Cancer Space Heats Up 5/22/2023

Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD

Mon, 05/22/2023 - 02:00
Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD 5/22/2023

Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD

Mon, 05/22/2023 - 02:00
Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD 5/22/2023

Krystal Gets First FDA Approval for Redosable Gene Therapy, Rare Skin Disease

Mon, 05/22/2023 - 02:00
Krystal Gets First FDA Approval for Redosable Gene Therapy, Rare Skin Disease 5/22/2023

Krystal Gets First FDA Approval for Redosable Gene Therapy, Rare Skin Disease

Mon, 05/22/2023 - 02:00
Krystal Gets First FDA Approval for Redosable Gene Therapy, Rare Skin Disease 5/22/2023

Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat

Mon, 05/22/2023 - 02:00
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat 5/22/2023

Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat

Mon, 05/22/2023 - 02:00
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat 5/22/2023

Biopharma Targets the Untapped Potential of the Human Healthspan

Mon, 05/22/2023 - 02:00
Biopharma Targets the Untapped Potential of the Human Healthspan 5/22/2023

Opinion: Sarepta Enters Uncharted Territory with Adcomm Approval

Mon, 05/22/2023 - 02:00
Opinion: Sarepta Enters Uncharted Territory with Adcomm Approval 5/22/2023

FDA Action Alert: Blueprint, Opiant and Lexicon

Mon, 05/22/2023 - 02:00
FDA Action Alert: Blueprint, Opiant and Lexicon 5/22/2023

ReCode–a New Contestant in the mRNA Race

Mon, 05/22/2023 - 02:00
ReCode–a New Contestant in the mRNA Race 5/22/2023

Intercept’s NASH Treatment Fails to Win Support of FDA Advisory Committee

Sat, 05/20/2023 - 02:00
Intercept’s NASH Treatment Fails to Win Support of FDA Advisory Committee 5/20/2023